Akèy › Kansè Poumon ki pa ti selil › Illinois › Arlington Heights
Etid klinik pou Kansè Poumon ki pa ti selil nan Arlington Heights, IL
12 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Arlington Heights (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Advocate Good Shepherd Hospital, Barrington · 9 mi lwen
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- Illinois Cancer Specialists, Arlington Heights
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Ap rekriteFaz 3
- Illinois Cancer Specialists, Arlington Heights
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
Ap rekriteEtid obsèvasyon
- Northwest Oncology & Hematology, Elk Grove Village · 6 mi lwen
An External Control Arm Study in Non-Small Cell Lung Cancer
Ap rekriteEtid obsèvasyon
- Northwest Oncology and Hematology, Rolling Meadows · 2 mi lwen
- Northwest Oncology and Hematology, Elk Grove · 6 mi lwen
- Northwest Oncology and Hematology, Hoffman Estates · 6 mi lwen
- ak 1 plis
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Ap rekriteFaz 2/3
- Local Institution - 007-883-A, Arlington Heights
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Ap rekriteFaz 3
- Illinois Cancer Specialists, Arlington Heights
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Ap rekriteFaz 3
- Northwest Oncology & Hematology, Barrington · 9 mi lwen
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Advocate Good Shepherd Hospital, Barrington · 9 mi lwen
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Advocate Good Shepherd Hospital, Barrington · 9 mi lwen
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Advocate Good Shepherd Hospital, Barrington · 9 mi lwen
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Advocate Good Shepherd Hospital, Barrington · 9 mi lwen
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan Arlington Heights
- Kansè kolorektal12 etid
- Kansè poumon9 etid
- Kansè nan tete7 etid
- Ensifizyans kadyak7 etid
- Kansè Metastatik6 etid
- Kolit Ulseratif6 etid
- Kansè kolon6 etid
- Kansè ovè5 etid
- Obèsite5 etid
- Sipwa5 etid
- Kansè pwostat3 etid
- Kondisyon po3 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.